CA1179264A - Condranol for transplants - Google Patents
Condranol for transplantsInfo
- Publication number
- CA1179264A CA1179264A CA000389215A CA389215A CA1179264A CA 1179264 A CA1179264 A CA 1179264A CA 000389215 A CA000389215 A CA 000389215A CA 389215 A CA389215 A CA 389215A CA 1179264 A CA1179264 A CA 1179264A
- Authority
- CA
- Canada
- Prior art keywords
- transplant
- coated
- implant
- coated surgical
- surgical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000007943 implant Substances 0.000 claims abstract description 33
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 9
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims abstract description 7
- 210000000056 organ Anatomy 0.000 claims abstract description 7
- 210000002216 heart Anatomy 0.000 claims description 4
- 210000003709 heart valve Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 8
- 238000002054 transplantation Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 4
- 238000002513 implantation Methods 0.000 abstract description 4
- 241000282412 Homo Species 0.000 abstract description 3
- 230000000399 orthopedic effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 26
- 239000003814 drug Substances 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010001496 Galectin 2 Proteins 0.000 description 1
- 102100021735 Galectin-2 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- 206010066902 Surgical failure Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000000332 continued effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 102220093061 rs139517777 Human genes 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/20—Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Prostheses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26378881A | 1981-05-14 | 1981-05-14 | |
US263,788 | 1981-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1179264A true CA1179264A (en) | 1984-12-11 |
Family
ID=23003232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000389215A Expired CA1179264A (en) | 1981-05-14 | 1981-11-02 | Condranol for transplants |
Country Status (7)
Country | Link |
---|---|
JP (1) | JPS57188522A (pt) |
CA (1) | CA1179264A (pt) |
DE (1) | DE3144236C2 (pt) |
DK (1) | DK70382A (pt) |
FR (1) | FR2505656A1 (pt) |
GB (1) | GB2098506B (pt) |
SE (1) | SE8107352L (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0121008A3 (en) * | 1983-03-29 | 1985-03-27 | Marcel E. Nimni | Coating for bioprosthetic device and method of making same |
GB2297931B (en) * | 1992-04-07 | 1996-10-16 | Wilhelm Env Tech Inc | Flue gas conditioning system |
WO1993019852A1 (en) * | 1992-04-07 | 1993-10-14 | Wilhelm Environmental Technologies, Inc. | Flue gas conditioning system |
WO2000027437A2 (en) * | 1998-11-11 | 2000-05-18 | The Board Of Regents Of The University Of Oklahoma | Polymer grafting by polysaccharide synthases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2037942C2 (de) * | 1970-04-15 | 1982-11-18 | Biomed Research, Inc., 90048 Los Angeles, Calif. | Arzneimittel enthaltend ein "aktives" Chondroitinsulfat als Wirkstoff zur Verhinderung des Auftretens atherosklerotischer Läsionen und zur Verhinderung des Auftretens von Herzanfällen |
US3895106A (en) * | 1970-04-15 | 1975-07-15 | Morrison L M | Novel CSA and CSC for use in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals |
JPS5235710A (en) * | 1975-09-16 | 1977-03-18 | Ulvac Corp | In-material-heat reflection plate device in heating furnaces |
US4302577A (en) * | 1979-10-05 | 1981-11-24 | Biomed Research Inc. | Process for preparing CSA or CSC |
-
1981
- 1981-09-10 GB GB8127345A patent/GB2098506B/en not_active Expired
- 1981-10-13 JP JP56162145A patent/JPS57188522A/ja active Pending
- 1981-11-02 CA CA000389215A patent/CA1179264A/en not_active Expired
- 1981-11-06 DE DE3144236A patent/DE3144236C2/de not_active Expired
- 1981-12-08 SE SE8107352A patent/SE8107352L/xx not_active Application Discontinuation
-
1982
- 1982-02-08 FR FR8201965A patent/FR2505656A1/fr active Pending
- 1982-02-17 DK DK70382A patent/DK70382A/da not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GB2098506B (en) | 1984-10-03 |
SE8107352L (sv) | 1982-11-15 |
GB2098506A (en) | 1982-11-24 |
DK70382A (da) | 1982-11-15 |
FR2505656A1 (fr) | 1982-11-19 |
DE3144236C2 (de) | 1987-04-30 |
DE3144236A1 (de) | 1982-11-25 |
JPS57188522A (en) | 1982-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7709017B2 (en) | Implantable preparations | |
US6949625B2 (en) | Injectable implant of insoluble globin | |
EP0285370B1 (en) | Injectable soft tissue augmentation materials from the placenta and their method of manufacture | |
US20140106447A1 (en) | Compositions and methods for recruiting stem cells | |
JP2002508673A (ja) | グラフト・プロテーゼとその材料及び方法 | |
JP2002526184A (ja) | 安全で効果的なバイオフィルム阻害化合物及びその健康関連の使用 | |
EP3349814B1 (en) | Non-gelling soluble extracellular matrix with biological activity | |
Williams | Biomaterials and tissue engineering in reconstructive surgery | |
JP2019508213A (ja) | 生体内分解率及び物性の調節が可能な生体適合性豚軟骨来由細胞外基質膜の製造方法及び前記豚軟骨来由細胞外基質を有効成分として含む癒着防止用組成物 | |
RU2721116C2 (ru) | Композиции для лечения поражений тканей | |
JP2022027930A (ja) | 幹細胞濾液製剤及びその調製方法 | |
CA1179264A (en) | Condranol for transplants | |
US5916553A (en) | Complex for inducing bone growth in the mastoid cavity | |
AU2004237992B2 (en) | Insoluble globin injectable implant | |
EP0191994B1 (en) | Solution for use in viscosurgery and/or as a vitreous substitute | |
Amudeswari et al. | Short‐term biocompatibility studies of hydrogel‐grafted collagen copolymers | |
RU2433828C1 (ru) | Инъекционный гетерогенный биополимерный гидрогель для заместительной и регенеративной хирургии и способ его получения | |
KR20220089586A (ko) | 복합기능성 유착방지용 약학조성물 | |
KR20010038098A (ko) | 헤파린 처리된 항석회화성 생체조직 이식물 및 이의 제조 방법 | |
CN116549485A (zh) | β-多肽或β-多肽聚合物在促进血管形成及抑制器官纤维化中的应用 | |
RU2135127C1 (ru) | Раствор для защиты и лечения заболеваний и повреждений роговицы "визитин" | |
Monhian et al. | The role of soft-tissue implants in scar revision | |
RU2058122C1 (ru) | Способ хирургической коррекции окклюзионных поражений сосудов | |
KR100342384B1 (ko) | 자가점막이식 기도 인공 삽입물 | |
Dental | Dorland Medical |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |